Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: Proposal of a modified Yonsei criteria score

Rho, Seoung Yoon; Yun, Mijin; Kang, Chang Moo; Lee, Sung Hwan; Hwang, Ho Kyoung; Lee, Woo Jung

doi:10.1016/j.pan.2018.09.001

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, precision medicine, including the prediction of a potentially systemic molecular subtype with clinically available biomarkers, is mandatory in managing resectable pancreatic cancer [12,13]. Despite the failure to find specific subtypes with oncological relevance to the treatment of pancreatic cancer [14], we tried to classify pancreatic cancers in order to individualize their treatment options [4,[15][16][17][18][19]. Previously, we identified precise strategies for resectable pancreatic cancer regarding clinically available biomarkers, such as metabolic phenotypes in PET scans [3].…”

Section: Discussionmentioning

confidence: 99%

MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Pancreatic cancer is a devastating disease with a high relapse rate, even in case of resectable pancreatic cancer. Here, we aimed to identify the prognostic significance and therapeutic options of metabolic subtypes of resectable pancreatic cancer. Method Transcriptomic data were obtained from the TCGA-PAAD cohort in the The Cancer Genome Atlas (TCGA) data portal (n = 182). After integrative analysis of transcriptomic data in the discovery cohort, immunohistochemical (IHC) staining was performed in an independent cohort (n = 51) to validate the molecules of interest. Experimental testing for the molecules of interest was performed in vitro using pancreatic cancer cell line models AsPC1, BxPC3, MIA PaCa-2 and PANC-1. Results Two subtypes showing distinct gene expression patterns in the TCGA-PAAD dataset were identified. Of these, the active glucose metabolism subtype showed a significantly lower survival rate related to relapse after surgical resection. The genes SLC2A1 (GLUT1) and SLC16A3 (MCT4) were highly enriched in this subtype. The validation cohort showed a high MCT4 staining and a high relapse rate (p = 0.01). Several molecular pathways associated with aggressive tumor biology, including cell cycle regulation and Myc and mTOR downstream signaling, were highly enriched in the active glucose metabolism subtype, as well as with distinct responses to immunotherapy. MCT4 inhibition suppressed the in vitro malignant characteristics of pancreatic cancer cells and showed a synergistic effect with gemcitabine treatment. Conclusions From our data we conclude that MCT4 may serve as a potential therapeutic target in resectable pancreatic cancer. The precision medicine strategy for resectable pancreatic cancer should be validated in a clinical setting with a prospective study design.

show abstract